ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLC
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf217 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Oncologist, 2025. Verfasst von Joyce Liang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Cancer Center, Massachusetts General Hospital, Boston, MA, United States. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Targeting a Cure for Lung Cancer Research Fund, Venanzi Fund.
Abstract (Originalsprache)
Objective
Despite advances in ALK inhibitors for ALK fusion-positive (ALK+) non–small-cell lung cancer (NSCLC), drug resistance remains a challenge. Studies of treatment outcomes and resistance biomarkers are imperative for drug development, yet patient representation can be limited. This study evaluated the feasibility of a decentralized research infrastructure to establish a clinical and biospecimen repository, broadening patient access and inclusion. Patients and methods Patients with advanced ALK+ NSCLC across the United States were enrolled through remote informed consent. Clinical history and tumor molecular profiling data were collected at baseline and during remote follow-ups. Archival tumor and saliva biospecimens (for germline sampling) were obtained for analysis.
Results
Of 87 eligible patients, 80 (92%) completed remote consent and enrolled. The clinical data collection rate was 100%, with archival tumor acquired from 80% and saliva samples from 65%. Patients represented 31 states, with 94% residing outside the study center’s state and 90% receiving care elsewhere. Next-generation sequencing was conducted on 55 treatment-naïve and 18 treatment-resistant biopsies, all of whom received at least one prior second-generation ALK inhibitor, and 9 received lorlatinib. ALK resistance mutations were identified in 54% of treatment-resistant biopsies; other commonly co-altered genes included TP53 (18%) and CDKN2A/B (16%).
Conclusions
This study highlights the feasibility of a decentralized design to enhance the inclusion of a broader patient population with ALK+ NSCLC. This establishes a scalable framework that may help overcome barriers to patient participation in research, with the goal of improving therapy development and patient outcomes. The Elucidating Novel Immune and Genomic Markers for ALK+ study accrual and analysis continue (NCT04881916).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Cancer Center, Massachusetts General Hospital, Boston, MA, United States.
- ALK Positive, Inc., Atlanta, GA, 30328, United States.
ORCID-Profile: Paige Roberts, Justin F Gainor, Jessica J Lin
Förderung
- NCI NIH HHS
- Targeting a Cure for Lung Cancer Research Fund
- Venanzi Fund
- National Cancer Institute
Zitieren
APA
Liang, J., Waliany, S., Do, A., Peterson, J. L., Roberts, P., Kennedy, E. A., Venanzi, E. S., Gainor, J. F., & Lin, J. J. (2025). ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLC. The Oncologist. https://doi.org/10.1093/oncolo/oyaf217
Vancouver
Liang J, Waliany S, Do A, Peterson JL, Roberts P, Kennedy EA, et al. ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLC. The Oncologist. 2025. doi:10.1093/oncolo/oyaf217
BibTeX
@article{Liang2025,
author = {Liang, Joyce and Waliany, Sarah and Do, Andrew and Peterson, Jennifer L and Roberts, Paige and Kennedy, Elizabeth A and Venanzi, Emily S and Gainor, Justin F and Lin, Jessica J},
title = {ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLC},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf217}
}
EUVIMED